Researchers from Singapore have recently introduced a mobile application that teaches diabetes patients about diabetic foot ulcers and self foot care.
WHAT IT DOES
Developed in consultation with clinicians from Tan Tock Seng Hospital (TTSH) and National Healthcare Group, the app called WellFeet delivers comprehensive patient education through animations in multiple languages, including English,...
Kakao Healthcare, the digital healthcare business of South Korean internet company Kakao Corporation, has partnered with Novo Nordisk to further develop its diabetes management service powered by mobile and AI technologies.
The two organisations recently signed a memorandum of understanding to launch a smart healthcare service to support patients with diabetes. According to a press release, Kakao...
Mass.-based insulin-pump maker Insulet acquired assets related to Bigfoot Biomedical's pump-based automated insulin delivery (AID) technologies for $25 million.
Insulet and Bigfoot offer two distinct forms of diabetes-management care: Insulet's Omnipod system that delivers insulin via a wearable, tubeless pump dubbed the Pod; and a remote controller called the Personal Diabetes Manager (PDM)....
Taiwan-based digital health startup Health2Sync and French multinational pharmaceutical firm Sanofi have signed another partnership to bring digital solutions for insulin management to Japan.
WHAT IT'S ABOUT
According to a press statement, both companies will jointly develop digitised features on insulin in Japan, including connected caps for insulin and titration alerts.
Health2Sync has a mobile...
Hong Seng's eMedAsia, CLEA partner to provide virtual COVID-19 screening for international travel
Malaysian digital health platform eMedAsia has started offering online COVID-19 testing services through its partnership with CLEA Technology.
Its partner provides virtual COVID-19 RTK and PCR screening services via the CLEADOC mobile app. It serves travellers who are seeking COVID-19 tests as a pre-...
Insulin pump-maker Insulet has scored FDA 510(k) clearance for its Omnipod 5 Automated Insulin Delivery System for people ages 6 and up with Type 1 diabetes. The pump integrates with the Dexcom G6 continuous glucose monitor to automatically adjust insulin levels depending on blood glucose. It can be worn for up to 72 hours.
Users can control their pump and share data from an app if they have a...
Digital diabetes and chronic condition management company Glooko announced Monday it had acquired Berlin-based xbird, maker of AI-based diabetes care tools.
xbird monitors patients' activity with sensors and wearables, using artificial intelligence and machine learning to find potential problems and alert users to take action, like a nudge to check blood glucose levels.
"xbird and Glooko are a...
Health2Sync, a digital health startup based in Taiwan, and French multinational pharmaceutical firm Sanofi have extended their collaboration to soon come up with and market a new insulin management solution.
WHY IT MATTERS
The companies noted the "suboptimal" use of insulin in Taiwan and Asia. A recent study published in the Journal of Diabetes Investigation shared that approximately half of...
Diabetes management technology company Intuity Medical announced Wednesday that its POGO Automatic Blood Glucose Monitoring System is available in the U.S.
The POGO system uses a cartridge with 10 test strips and lancets contained in one device, allowing users to test their glucose without carrying around separate supplies.
The device can also connect via Bluetooth to the Patterns app, which...
Remote continuous data monitoring – a personalised, tech-focused approach to diabetes management employed by one Dubai-based specialist clinic – continues to demonstrate positive results in its patients, it has been confirmed.
Six months since the release of its first report showcasing preliminary outcomes of its care model, GluCare Integrated Diabetes Center has now published a second set of...
.jpg?itok=VK-bK2jP "The Dubai-based GluCare Integrated Diabetes Center has published a second set of clinical results revealing further reduction of haemoglobin A1c (HbA1c) levels in its patients.")
